Investigational Drug Details
| Drug ID: | D292 |
| Drug Name: | Dopamine |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB00988 |
| DrugBank Description: | One of the catecholamine neurotransmitters in the brain. It is derived from tyrosine and is the precursor to norepinephrine and epinephrine. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (receptors, dopamine) mediate its action. |
| PubChem ID: | 681 |
| CasNo: | 51-61-6 |
| Repositioning for NAFLD: | Yes |
| SMILES: | NCCC1=CC(O)=C(O)C=C1 |
| Structure: |
|
| InChiKey: | VYFYYTLLBUKUHU-UHFFFAOYSA-N |
| Molecular Weight: | 153.1784 |
| DrugBank Targets: | Dopamine D2 receptor; Dopamine D1 receptor; Dopamine D5 receptor; Dopamine D3 receptor; Dopamine D4 receptor; Sodium-dependent dopamine transporter; Dopamine beta-hydroxylase; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 7; D(1) dopamine receptor; Sodium-dependent noradrenaline transporter; Sodium-dependent serotonin transporter; 5-hydroxytryptamine receptor 3A; 5-hydroxytryptamine receptor 3B; Superoxide dismutase [Cu-Zn]; Synaptic vesicular amine transporter |
| DrugBank MoA: | Dopamine is a precursor to norepinephrine in noradrenergic nerves and is also a neurotransmitter in certain areas of the central nervous system. Dopamine produces positive chronotropic and inotropic effects on the myocardium, resulting in increased heart rate and cardiac contractility. This is accomplished directly by exerting an agonist action on beta-adrenoceptors and indirectly by causing release of norepinephrine from storage sites in sympathetic nerve endings. In the brain, dopamine actas as an agonist to the five dopamine receptor subtypes (D!, D2, D3, D4, D5). |
| DrugBank Pharmacology: | Dopamine is a natural catecholamine formed by the decarboxylation of 3,4-dihydroxyphenylalanine (DOPA). It is a precursor to norepinephrine in noradrenergic nerves and is also a neurotransmitter in certain areas of the central nervous system, especially in the nigrostriatal tract, and in a few peripheral sympathetic nerves. Dopamine produces positive chronotropic and inotropic effects on the myocardium, resulting in increased heart rate and cardiac contractility. This is accomplished directly by exerting an agonist action on beta-adrenoceptors and indirectly by causing release of norepinephrine from storage sites in sympathetic nerve endings. |
| DrugBank Indication: | For the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L1718 | NCT00077597 | PHASE3 | COMPLETED | NO | 2004-02 | 2016-11-02 | Details |
| L3669 | NCT01934712 | PHASE1 | COMPLETED | NO | 2013-08-30 | 2018-12-11 | Details |
| L4165 | NCT00231634 | PHASE3 | TERMINATED | NO | 2001-05 | 2011-06-08 | Details |
| L4278 | NCT01565096 | PHASE4 | UNKNOWN | NO | 2011-11 | 2012-03-28 | Details |
| L4429 | NCT01495013 | PHASE3 | COMPLETED | NO | 2011-12 | 2016-11-21 | Details |
| L6610 | NCT02771093 | PHASE4 | COMPLETED | YES | 2016-09-08 | 2023-12-12 | Details |
| L6677 | NCT01767688 | PHASE1 | COMPLETED | YES | 2013-01-16 | 2018-09-10 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|